Corrigendum: Safety of Semaglutide.

Smits, Mark M; Van Raalte, Daniël H.

Smits MM; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.
Van Raalte DH; Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.

Front Endocrinol (Lausanne) ; 12: 786732, 2021.

Article en En | MEDLINE | ID: mdl-34858353

Palabras clave

glucagon-like peptide-1 receptor agonist (GLP-1RA); oral; safety; semaglutide; subcutaneous; type 2 diabetes

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article